|
1
|
Bosch FX, Ribes J, Díaz M and Cléries R:
Primary liver cancer: worldwide incidence and trends.
Gastroenterology. 127(Suppl 1): S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
LeRoith D and Roberts CT Jr: The
insulin-like growth factor system and cancer. Cancer Lett.
195:127–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pollak MN, Schernhammer ES and Hankinson
SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer.
4:505–518. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khandwala HM, McCutcheon IE, Flyvbjerg A
and Friend KE: The effects of insulin-like growth factors on
tumorigenesis and neoplastic growth. Endocr Rev. 21:215–244. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baserga R: Oncogenes and the strategy of
growth factors. Cell. 79:927–930. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reynolds AR and Kyprianou N: Growth factor
signalling in prostatic growth: significance in tumour development
and therapeutic targeting. Br J Pharmacol. 147(Suppl 2): S144–S152.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Scharf JG and Braulke T: The role of the
IGF axis in hepatocar-cinogenesis. Horm Metab Res. 35:685–693.
2003. View Article : Google Scholar
|
|
8
|
Alexia C, Fallot G, Lasfer M,
Schweizer-Groyer G and Groyer A: An evaluation of the role of
insulin-like growth factors (IGF) and of type-I IGF receptor
signalling in hepatocarcinogenesis and in the resistance of
hepatocarcinoma cells against drug-induced apoptosis. Biochem
Pharmacol. 68:1003–1015. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen ZW, Ahren B, Ostenson CG, Cintra A,
Bergman T, Möller C, Fuxe K, Mutt V, Jörnvall H and Efendic S:
Identification, isolation, and characterization of daintain
(allograft inflammatory factor 1), a macrophage polypeptide with
effects on insulin secretion and abundantly present in the pancreas
of prediabetic BB rats. Proc Natl Acad Sci USA. 94:13879–13884.
1997. View Article : Google Scholar
|
|
10
|
Utans U, Arceci RJ, Yamashita Y and
Russell ME: Cloning and characterization of allograft inflammatory
factor-1: a novel macrophage factor identified in rat cardiac
allografts with chronic rejection. J Clin Invest. 95:2954–2962.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tian Y, Kelemen SE and Autieri MV:
Inhibition of AIF-1 expression by constitutive siRNA expression
reduces macrophage migration, proliferation, and signal
transduction initiated by atherogenic stimuli. Am J Physiol Cell
Physiol. 290:C1083–C1091. 2006. View Article : Google Scholar
|
|
12
|
Yang ZF, Ho DW, Lau CK, Lam CT, Lum CT,
Poon RT and Fan ST: Allograft inflammatory factor-1 (AIF-1) is
crucial for the survival and pro-inflammatory activity of
macrophages. Int Immunol. 17:1391–1397. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kimura M, Kawahito Y, Obayashi H, Ohta M,
Hara H, Adachi T, Tokunaga D, Hojo T, Hamaguchi M, Omoto A, et al:
A critical role for allograft inflammatory factor-1 in the
pathogenesis of rheumatoid arthritis. J Immunol. 178:3316–3322.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Del Galdo F, Maul GG, Jiménez SA and
Artlett CM: Expression of allograft inflammatory factor 1 in
tissues from patients with systemic sclerosis and in vitro
differential expression of its isoforms in response to transforming
growth factor beta. Arthritis Rheum. 54:2616–2625. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pashenkov M, Efendic S, Zhu J, Zou LP,
Ostenson CG and Mustafa M: Augmented expression of
daintain/allograft inflammatory factor-1 is associated with
clinical disease: dynamics of daintain/allograft inflammatory
factor-1 expression in spleen, peripheral nerves and sera during
experimental autoimmune neuritis. Scand J Immunol. 52:117–122.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu S, Tan WY, Chen QR, Chen XP, Fu K,
Zhao YY and Chen ZW: Daintain/AIF-1 promotes breast cancer
proliferation via activation of the NF-kappaB/cyclin D1 pathway and
facilitates tumor growth. Cancer Sci. 99:952–957. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li T, Feng Z, Jia S, Wang W, Du Z, Chen N
and Chen Z: Daintain/AIF-1 promotes breast cancer cell migration by
up-regulated TNF-α via activate p38 MAPK signaling pathway. Breast
Cancer Res Treat. 131:891–898. 2012. View Article : Google Scholar
|
|
18
|
Balkwill F and Mantovani A: Inflammation
and cancer: back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Naugler WE, Sakurai T, Kim S, Maeda S, Kim
K, Elsharkawy AM and Karin M: Gender disparity in liver cancer due
to sex differences in MyD88-dependent IL-6 production. Science.
317:121–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fausto N, Campbell JS and Riehle KJ: Liver
regeneration. Hepatology. 43(Suppl 1): S45–S53. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nagakawa Y, Nomoto S, Kato Y, Montgomery
RA, Williams GM, Klein AS and Sun Z: over-expression of AIF-1 in
liver allografts and peripheral blood correlates with acute
rejection after transplantation in rats. Am J Transplant.
4:1949–1957. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hirsch J, Hansen KC, Choi S, Noh J, Hirose
R, Roberts JP, Matthay MA, Burlingame AL, Maher JJ and Niemann CU:
Warm ischemia-induced alterations in oxidative and inflammatory
proteins in hepatic Kupffer cells in rats. Mol Cell Proteomics.
5:979–986. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huynh H, Chow PK, Ooi LL and Soo KC: A
possible role for insulin-like growth factor-binding protein-3
autocrine/paracrine loops in controlling hepatocellular carcinoma
cell proliferation. Cell Growth Differ. 13:115–122. 2002.PubMed/NCBI
|
|
24
|
Aishima S, Basaki Y, Oda Y, Kuroda Y,
Nishihara Y, Taguchi K, Taketomi A, Maehara Y, Hosoi F, Maruyama Y,
et al: High expression of insulin-like growth factor binding
protein-3 is correlated with lower portal invasion and better
prognosis in human hepatocellular carcinoma. Cancer Sci.
97:1182–1190. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lund P, Schubert D, Niketeghad F and
Schirmacher P: Autocrine inhibition of chemotherapy response in
human liver tumor cells by insulin-like growth factor-II. Cancer
Lett. 206:85–96. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Firth SM and Baxter RC: Cellular actions
of the insulin-like growth factor binding proteins. Endocr Rev.
23:824–854. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yakar S, Wu Y, Setser J and Rosen CJ: The
role of circulating IGF-I: lessons from human and animal models.
Endocrine. 19:239–248. 2002. View Article : Google Scholar
|
|
28
|
Bach LA, Headey SJ and Norton RS:
IGF-binding proteins - the pieces are falling into place. Trends
Endocrinol Metab. 16:228–234. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Adams TE, Epa VC, Garrett TP and Ward CW:
Structure and function of the type 1 insulin-like growth factor
receptor. Cell Mol Life Sci. 57:1050–1093. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Butler AA, Yakar S, Gewolb IH, Karas M,
Okubo Y and LeRoith D: Insulin-like growth factor-I receptor signal
transduction: at the interface between physiology and cell biology.
Comp Biochem Physiol B Biochem Mol Biol. 121:19–26. 1998.
View Article : Google Scholar
|
|
31
|
Dearth RK, Cui X, Kim HJ, Hadsell DL and
Lee AV: Oncogenic transformation by the signaling adaptor proteins
insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle.
6:705–713. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hashemolhosseini S, Nagamine Y, Morley SJ,
Desrivières S, Mercep L and Ferrari S: Rapamycin inhibition of the
G1 to S transition is mediated by effects on cyclin D1 mRNA and
protein stability. J Biol Chem. 273:14424–14429. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen Y, Knudsen ES and Wang JY: The
RB/p107/p130 phosphorylation pathway is not inhibited in
rapamycin-induced G1-prolongation of NIH3T3 cells. Oncogene.
13:1765–1771. 1996.PubMed/NCBI
|
|
34
|
Gao N, Flynn DC, Zhang Z, Zhong XS, Walker
V, Liu KJ, Shi X and Jiang BH: G1 cell cycle progression and the
expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1
signaling in human ovarian cancer cells. Am J Physiol Cell Physiol.
287:C281–C291. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Burkhart DL and Sage J: Cellular
mechanisms of tumour suppression by the retinoblastoma gene. Nat
Rev Cancer. 8:671–682. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Santamaria D and Ortega S: Cyclins and
CDKS in development and cancer: lessons from genetically modified
mice. Front Biosci. 11:1164–1188. 2006. View Article : Google Scholar
|
|
37
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: a changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lindqvist A, Rodríguez-Bravo V and Medema
RH: The decision to enter mitosis: feedback and redundancy in the
mitotic entry network. J Cell Biol. 185:193–202. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schuuring E, Verhoeven E, Mooi WJ and
Michalides RJ: Identification and cloning of two overexpressed
genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13
region in human carcinomas. Oncogene. 7:355–361. 1992.PubMed/NCBI
|
